Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Autor:	Gottlieb RL; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas, Texas., Nirula A; Eli Lilly and Company, Indianapolis, Indiana., Chen P; Department of Medicine, Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, California., Boscia J; Vitalink Research, Union, South Carolina., Heller B; Long Beach Clinical Trials, Long Beach, California., Morris J; Imperial Health, Lake Charles, Louisiana., Huhn G; Cook County Health, Chicago, Illinois., Cardona J; Indago Research, Hialeah, Florida., Mocherla B; Las Vegas Medical Research Center, Las Vegas, Nevada., Stosor V; Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Shawa I; Franciscan Health, Greenwood, Indiana., Kumar P; Georgetown University, Washington, DC., Adams AC; Eli Lilly and Company, Indianapolis, Indiana., Van Naarden J; Eli Lilly and Company, Indianapolis, Indiana., Custer KL; Eli Lilly and Company, Indianapolis, Indiana., Durante M; Eli Lilly and Company, Indianapolis, Indiana., Oakley G; Eli Lilly and Company, Indianapolis, Indiana., Schade AE; Eli Lilly and Company, Indianapolis, Indiana., Holzer TR; Eli Lilly and Company, Indianapolis, Indiana., Ebert PJ; Eli Lilly and Company, Indianapolis, Indiana., Higgs RE; Eli Lilly and Company, Indianapolis, Indiana., Kallewaard NL; Eli Lilly and Company, Indianapolis, Indiana., Sabo J; Eli Lilly and Company, Indianapolis, Indiana., Patel DR; Eli Lilly and Company, Indianapolis, Indiana., Klekotka P; Eli Lilly and Company, Indianapolis, Indiana., Shen L; Eli Lilly and Company, Indianapolis, Indiana., Skovronsky DM; Eli Lilly and Company, Indianapolis, Indiana.
Jazyk:	angličtina
Zdroj:	JAMA [JAMA] 2021 Feb 16; Vol. 325 (7), pp. 632-644.
DOI:	10.1001/jama.2021.0202
Abstrakt:	Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19. Design, Setting, and Participants: The BLAZE-1 study is a randomized phase 2/3 trial at 49 US centers including ambulatory patients (N = 613) who tested positive for SARS-CoV-2 infection and had 1 or more mild to moderate symptoms. Patients who received bamlanivimab monotherapy or placebo were enrolled first (June 17-August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22-September 3). These are the final analyses and represent findings through October 6, 2020. Interventions: Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n = 101], 2800 mg [n = 107], or 7000 mg [n = 101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of etesevimab [n = 112]), or placebo (n = 156). Main Outcomes and Measures: The primary end point was change in SARS-CoV-2 log viral load at day 11 (±4 days). Nine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo, and included 3 other measures of viral load, 5 on symptoms, and 1 measure of clinical outcome (the proportion of patients with a COVID-19-related hospitalization, an emergency department [ED] visit, or death at day 29). Results: Among the 577 patients who were randomized and received an infusion (mean age, 44.7 [SD, 15.7] years; 315 [54.6%] women), 533 (92.4%) completed the efficacy evaluation period (day 29). The change in log viral load from baseline at day 11 was -3.72 for 700 mg, -4.08 for 2800 mg, -3.49 for 7000 mg, -4.37 for combination treatment, and -3.80 for placebo. Compared with placebo, the differences in the change in log viral load at day 11 were 0.09 (95% CI, -0.35 to 0.52; P = .69) for 700 mg, -0.27 (95% CI, -0.71 to 0.16; P = .21) for 2800 mg, 0.31 (95% CI, -0.13 to 0.76; P = .16) for 7000 mg, and -0.57 (95% CI, -1.00 to -0.14; P = .01) for combination treatment. Among the secondary outcome measures, differences between each treatment group vs the placebo group were statistically significant for 10 of 84 end points. The proportion of patients with COVID-19-related hospitalizations or ED visits was 5.8% (9 events) for placebo, 1.0% (1 event) for 700 mg, 1.9% (2 events) for 2800 mg, 2.0% (2 events) for 7000 mg, and 0.9% (1 event) for combination treatment. Immediate hypersensitivity reactions were reported in 9 patients (6 bamlanivimab, 2 combination treatment, and 1 placebo). No deaths occurred during the study treatment. Conclusions and Relevance: Among nonhospitalized patients with mild to moderate COVID-19 illness, treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11; no significant difference in viral load reduction was observed for bamlanivimab monotherapy. Further ongoing clinical trials will focus on assessing the clinical benefit of antispike neutralizing antibodies in patients with COVID-19 as a primary end point. Trial Registration: ClinicalTrials.gov Identifier: NCT04427501.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu